2Hodi FS, CKDay SJ, McDermott DF, et al. Improved survival withipilimumab in patients with metastatic melanoma. N Engl J Med,2010,363(8): 711-723.
3Kong Y, Si L, Guo J, et al. Aberrations of KIT, BRAF, NRAS, andPDGFRA in Chinese melanoma patients and their significance:Large, scale analysis of 644 patients. J Clin Oncol, 2011, 29(15): 8568.
4Ellerhorst JA, Greene VR,Ekmekcioglu S,et al. Clinical corre-lates of NRAS and BRAF mutations in primary humanmelanoma. Clin Cancer Res, 2011, 17(2): 229-235.
5Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF genein human cancer. Nature, 2002, 417(6892): 949-954.
6Brose MS, Volpe P,Feldman M, et al. BRAF and RAS mutationsin human lung cancer and melanoma. Cancer Res, 2002, 62(23): 6997-7000.
7Goel VK, Lazar AJ, Wameke CL, et al. Examination of mutationsin BRAF, NRAS, and PTEN in primary cutaneous melanomajInvest Dermatol, 2006, 126(1): 154-160.
8Dhomen N,Marais R. BRAF signaling and targeted therapies inmelanoma. Hematol Oncol Clin North Am, 2009, 23 (3): 529-545.
9Noveski L, Zhivadinovik J, Matveeva N. Prognostic factors of primary cutaneus melanoma[J]. Med Pregl, 2014, 67(11-12):392-398.
10Eriksson H, Frohm-Nilsson M, J?r?s J, et al. Prognostic factors in localized invasive primary cutaneous malignant melanoma:results of a large population-based study[J]. Br J Dermatol, 2015, 172(1):175-186.
